We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-6.51%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.59B
AUM Growth
-$241M
Cap. Flow
-$119M
Cap. Flow %
-7.49%
Top 10 Hldgs %
53.34%
Holding
89
New
20
Increased
22
Reduced
13
Closed
28

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$50.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$41.3M
3
LOW icon
Lowe's Companies
LOW
+$36.2M
4
UTHR icon
United Therapeutics
UTHR
+$30.3M
5
RH icon
RH
RH
+$23.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$40.8M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$37.9M
3
AZO icon
AutoZone
AZO
+$28.7M
4
BIIB icon
Biogen
BIIB
+$28.2M
5
PLYA
Playa Hotels & Resorts
PLYA
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Consumer Discretionary 15.3%
3 Industrials 5.59%
4 Consumer Staples 4.92%
5 Technology 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$396M 24.94%
1,350,000
-250,000
-16% -$72M
AVTX icon
2
Avalo Therapeutics
AVTX
$1.02B
$100M 6.32%
6,399
+43
+0.7% +$652K
ENR icon
3
Energizer
ENR
$1.39B
$52.1M 3.28%
1,348,000
+52,000
+4% +$2.33M
DFRG
4
DELISTED
Del Frisco's Restaurant Group, Inc. Common Stock
DFRG
$48.8M 3.07%
6,125,000
+525,000
+9% +$3.47M
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$327M
$44.5M 2.81%
+3,158,000
New +$50.3M
HAIN icon
6
CALL
Hain Celestial
HAIN
$50.6M
$43.8M 2.76%
2,000,000
+400,000
+25% +$8.77M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.8B
$42.8M 2.7%
408,000
-17,000
-4% -$1.82M
EPC icon
8
Edgewell Personal Care
EPC
$1.37B
$41.5M 2.62%
1,540,000
+568,000
+58% +$20.3M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$70.9B
$38.8M 2.45%
+124,000
New +$41.3M
BURL icon
10
Burlington
BURL
$21.7B
$38.1M 2.4%
224,000
+24,000
+12% +$3.92M
AMAG
11
DELISTED
AMAG Pharmaceuticals
AMAG
$38M 2.39%
3,800,000
+484,000
+15% +$5.22M
CELG
12
DELISTED
Celgene Corp
CELG
$37M 2.33%
400,000
-192,000
-32% -$18.2M
WBT
13
DELISTED
Welbilt, Inc.
WBT
$36.6M 2.31%
2,192,000
+192,000
+10% +$3.14M
LOW icon
14
Lowe's Companies
LOW
$117B
$34.6M 2.18%
+343,000
New +$36.2M
MNK
15
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$33M 2.08%
+3,600,000
New +$52M
CLVS
16
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$32.9M 2.08%
+2,215,600
New +$40M
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$400M
$32.1M 2.02%
380,000
+8,000
+2% +$720K
ASMB icon
18
Assembly Biosciences
ASMB
$531M
$27M 1.7%
166,667
+72,667
+77% +$13.8M
RH icon
19
RH
RH
$3.56B
$25.9M 1.63%
+224,000
New +$23.1M
SJM icon
20
J.M. Smucker
SJM
$12B
$25.8M 1.63%
224,000
+124,000
+124% +$15.1M
FIVE icon
21
Five Below
FIVE
$11.2B
$25.6M 1.61%
213,000
+141,000
+196% +$18.6M
VYGR icon
22
Voyager Therapeutics
VYGR
$192M
$25.5M 1.61%
936,000
-600,000
-39% -$13.7M
UTHR icon
23
United Therapeutics
UTHR
$22.7B
$25.3M 1.59%
+324,000
New +$30.3M
DBX icon
24
Dropbox
DBX
$7.14B
$23.8M 1.5%
950,000
+700,000
+280% +$16.2M
FTDR icon
25
Frontdoor
FTDR
$5.32B
$21.8M 1.37%
500,000
-632,000
-56% -$24.3M
1
2 3 4

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Armistice Capital held 89 positions worth $1.59B, down 13% from $1.83B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Armistice Capital withdrew a net $119M in Q2 2019, closing 28 positions and reducing 13 holdings. Its most notable exit was Pacira BioSciences, an estimated $40.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Armistice Capital opened a new position in Vanda Pharmaceuticals worth $44.5M.

  • Armistice Capital's largest Q2 2019 buy was Vanda Pharmaceuticals: 3,158,000 shares worth $44.5M.
  • Armistice Capital added most to Edgewell Personal Care in Q2 2019, an estimated $20.3M increase.
  • Armistice Capital's biggest Q2 2019 reduction was Biogen, cutting an estimated $28.2M.
  • Armistice Capital fully exited Pacira BioSciences in Q2 2019, selling an estimated $40.8M.
  • Armistice Capital's ten largest holdings make up 53% of its $1.59B portfolio in Q2 2019.
  • Armistice Capital opened 20 new positions and closed 28 in Q2 2019.
  • Armistice Capital's portfolio value fell 13% quarter-over-quarter to $1.59B.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.